Baidu
map

Nanoscale:UTMD辅助PDT和基因治疗或可有效治疗三阴乳腺癌

2018-11-01 MedSci MedSci原创

三阴乳腺癌(TNBC)是一种侵袭性乳腺癌,由于缺乏孕激素受体(PR)、雌激素受体(ER)和HER2的表达,TNBC的复发率和整体存活率均差于其他乳腺癌亚型。为了提高TNBC的治疗效果,我们开发了一种新型多功能阳离子卟啉接枝脂质(CPGL)微泡,载有HIF1αsiRNA(siHIF@CpMB)。 由于CPGL的两亲结构,它可以与常规脂质自组装成微泡(MB),卟啉基团可以用作光动力疗法(PDT)

三阴乳腺癌(TNBC)是一种侵袭性乳腺癌,由于缺乏孕激素受体(PR)、雌激素受体(ER)和HER2的表达,TNBC的复发率和整体存活率均差于其他乳腺癌亚型。为了提高TNBC的治疗效果,我们开发了一种新型多功能阳离子卟啉接枝脂质(CPGL)微泡,载有HIF1αsiRNA(siHIF@CpMB)。

由于CPGL的两亲结构,它可以与常规脂质自组装成微泡(MB),卟啉基团可以用作光动力疗法(PDT)的光敏剂,而氨基可以通过静电吸附吸附HIF1αsiRNA(siHIF)。这种MB具有非常高的药物负载含量和较少的过早药物释放。通过实时US成像(3-12 MHz)可以轻松监控MB的分布。此外,借助超声靶向微泡破坏(UTMD),siHIF@CpMBs可以有效地原位转化为纳米粒子,通过空化效应促进卟啉和siRNA在肿瘤部位的积聚。HIF1αsiRNA下调HIF1α的表达水平,其由常见的缺氧肿瘤环境或ROS(由PDT产生)诱导,增强PDT功效并部分抑制肿瘤进展。

因此,UTMD辅助PDT和基因治疗的组合是治疗TNBC的有效策略。

原始出处:

Sun S, Xu Y, et al., Ultrasound-targeted photodynamic and gene dual therapy for effectively inhibiting triple negative breast cancer by cationic porphyrin lipid microbubbles loaded with HIF1α-siRNA. Nanoscale. 2018 Oct 22. doi: 10.1039/c8nr03074j. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793667, encodeId=e90b1e9366751, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Oct 08 04:08:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777173, encodeId=49bb1e77173d7, content=<a href='/topic/show?id=fdae1e555d6' target=_blank style='color:#2F92EE;'>#TMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17555, encryptionId=fdae1e555d6, topicName=TMD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2139104424, createdName=fanweitanzhen, createdTime=Thu Dec 06 13:08:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661518, encodeId=b11c166151863, content=<a href='/topic/show?id=73a3139e4e9' target=_blank style='color:#2F92EE;'>#PDT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13974, encryptionId=73a3139e4e9, topicName=PDT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e35e25313849, createdName=江川靖瑶, createdTime=Wed May 22 00:08:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619528, encodeId=d68d1619528a3, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 03 03:08:00 CST 2018, time=2018-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793667, encodeId=e90b1e9366751, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Oct 08 04:08:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777173, encodeId=49bb1e77173d7, content=<a href='/topic/show?id=fdae1e555d6' target=_blank style='color:#2F92EE;'>#TMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17555, encryptionId=fdae1e555d6, topicName=TMD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2139104424, createdName=fanweitanzhen, createdTime=Thu Dec 06 13:08:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661518, encodeId=b11c166151863, content=<a href='/topic/show?id=73a3139e4e9' target=_blank style='color:#2F92EE;'>#PDT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13974, encryptionId=73a3139e4e9, topicName=PDT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e35e25313849, createdName=江川靖瑶, createdTime=Wed May 22 00:08:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619528, encodeId=d68d1619528a3, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 03 03:08:00 CST 2018, time=2018-11-03, status=1, ipAttribution=)]
    2018-12-06 fanweitanzhen
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793667, encodeId=e90b1e9366751, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Oct 08 04:08:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777173, encodeId=49bb1e77173d7, content=<a href='/topic/show?id=fdae1e555d6' target=_blank style='color:#2F92EE;'>#TMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17555, encryptionId=fdae1e555d6, topicName=TMD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2139104424, createdName=fanweitanzhen, createdTime=Thu Dec 06 13:08:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661518, encodeId=b11c166151863, content=<a href='/topic/show?id=73a3139e4e9' target=_blank style='color:#2F92EE;'>#PDT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13974, encryptionId=73a3139e4e9, topicName=PDT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e35e25313849, createdName=江川靖瑶, createdTime=Wed May 22 00:08:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619528, encodeId=d68d1619528a3, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 03 03:08:00 CST 2018, time=2018-11-03, status=1, ipAttribution=)]
    2019-05-22 江川靖瑶
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793667, encodeId=e90b1e9366751, content=<a href='/topic/show?id=e40315955e3' target=_blank style='color:#2F92EE;'>#scale#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15955, encryptionId=e40315955e3, topicName=scale)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Oct 08 04:08:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777173, encodeId=49bb1e77173d7, content=<a href='/topic/show?id=fdae1e555d6' target=_blank style='color:#2F92EE;'>#TMD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17555, encryptionId=fdae1e555d6, topicName=TMD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2139104424, createdName=fanweitanzhen, createdTime=Thu Dec 06 13:08:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661518, encodeId=b11c166151863, content=<a href='/topic/show?id=73a3139e4e9' target=_blank style='color:#2F92EE;'>#PDT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13974, encryptionId=73a3139e4e9, topicName=PDT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e35e25313849, createdName=江川靖瑶, createdTime=Wed May 22 00:08:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619528, encodeId=d68d1619528a3, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 03 03:08:00 CST 2018, time=2018-11-03, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map